China Universal Asset Management Co., Ltd. has recently submitted its latest 13F-HR filing, detailing significant holdings in various companies. This filing, dated October 27, 2026, is crucial as it provides insights into the firm’s investment strategies and asset management approaches.

The filing indicates a total reported value of $1,918,365,201 in assets under management, showcasing the firm's commitment to diversifying its portfolio across multiple sectors. Notably, the report includes substantial investments in companies such as 10X Genomics Inc., AbbVie Inc., and Aardvark Therapeutics Inc., among others.

Background

China Universal Asset Management Co., Ltd. is a prominent player in the asset management industry, focusing on investment strategies that encompass a wide range of sectors, including healthcare and technology. The firm is headquartered in Shanghai, China, and operates under the Central Index Key (CIK) number 0001906594. The company has been active in filing various reports with the SEC, including multiple 13F-HR submissions throughout 2026.

What the Filing Says

The latest filing reveals that China Universal Asset Management has reported holdings in 522 different companies. The firm’s Chief Compliance Officer, Li Peng, signed the filing, which reflects the company's ongoing commitment to transparency and compliance in its investment activities.

"The total value of reported assets is $1,918,365,201," the filing states.

Impact

This filing is significant not only for China Universal Asset Management but also for the broader asset management industry. It highlights the competitive landscape where firms are increasingly focusing on building diverse portfolios to mitigate risks and capitalize on market opportunities. The reported holdings may influence how other asset managers adjust their strategies in response to market trends.

What's Next

The filing does not specify any immediate next steps for China Universal Asset Management. However, it is expected that the firm will continue to monitor its investments closely and adapt its strategies as necessary in response to market developments.